NASDAQ$ANIK

Anika Therapeutics Inc · Q1 2021 earnings

Q1 2021 earnings · · Investor relations

Briefing

Reported first quarter financial results with revenue slightly lower than pre-COVID levels but joint preservation revenue increased.

Anika Therapeutics reported its first quarter 2021 financial results, showing a slight decrease in revenue compared to pre-COVID levels in the prior year. However, the company's Joint Preservation revenue saw a significant increase of 55%. The company is maintaining its expectations for revenue growth in 2021.

  • Revenue was slightly lower compared to pre-COVID levels in the prior year.
  • Joint Preservation revenue increased by 55%.
  • Joint Preservation and Restoration grew to 36% of total revenues.
  • Company expects solid revenue growth, positive adjusted EBITDA and positive cash flows for 2021.

Headline financials

Total Revenue

$34.3M

Previous: $35.4M-3.1%
EPS (adj)

$0.06

Previous: $0.45-86.7%
Capital Expenditures

-$417K

Previous: -$723K+42.3%
Free Cash Flow

$2.42M

Previous: $5.07M-52.2%
Net Income

$2.84M

Previous: $5.79M-51.0%
Operating Income

$1.26M

Previous: $7.09M-82.3%
Gross Profit

$21M

Previous: $21.2M-1.1%
Cash & Equivalents

$94.6M

Previous: $65.8M+43.7%
Total Assets

$362M

Previous: $399M-9.2%
Stock-Based Comp

$2.26M

Previous: -$207K+1191.3%

Revenue & EPS history

Anika · Revenue · Quarterly

$34.3M

Q1 2021-3.1%vs Q1 2020
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Forward guidance

Anika Therapeutics anticipates upper 20% to low 30% revenue growth in Joint Preservation and Restoration, low single-digit growth in Joint Pain Management, and a mid single-digit decline in its Other product family, resulting in total company high single-digit to low double-digit percent revenue growth.

Tailwinds

  • Upper 20% to low 30% revenue growth in Joint Preservation and Restoration
  • Low single-digit growth in Joint Pain Management
  • Total company high single-digit to low double-digit percent revenue growth

Headwinds

  • Continued uncertainty in the global market associated with the impact of the COVID pandemic
  • Mid single-digit decline in its Other product family
  • Outlook is subject to changing dynamics associated with COVID, including vaccine distribution and COVID variants
  • Impact of COVID on elective procedures and related ordering patterns in Joint Pain Management
  • Potential for delays in elective procedures due to COVID-19

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

+0.1%

Avg return

Earnings day

-3.0%

Avg return

5 days after

-2.8%

Avg return

30 days after

51%

33 / 65 earnings

Positive

+32.1%

Q3 2019

Best reaction

-33.0%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-18.8%-4.7%-4.8%
Q4 2025+16.8%+31.6%+30.5%
Q3 2025+0.8%-0.5%+2.1%
Q1 2025-20.7%-23.2%-23.0%
Q4 2024-11.1%-7.3%-20.3%
Q3 2024-33.0%-34.0%-28.2%
Q2 2024-1.0%-3.6%-5.4%
Q1 2024-10.9%-9.9%-9.1%
Q4 2023-4.8%-2.0%-3.1%
Q3 2023+7.4%+6.7%+15.2%
Q2 2023-4.9%-12.7%-18.0%
Q1 2023-2.8%-3.2%+3.2%
Q4 2022-18.0%-17.4%-10.4%
Q3 2022+0.3%+5.3%+6.3%
Q2 2022-4.9%-2.7%-6.0%
Q1 2022-4.9%-3.8%+1.1%
Q4 2021-15.9%-18.0%-20.1%
Q3 2021+3.1%-8.2%-12.8%
Q2 2021+1.0%+0.8%+1.3%
Q1 2021+1.3%+2.8%+10.9%
Q4 2020-10.5%-12.1%+3.9%
Q3 2020-3.3%+0.2%+7.6%
Q2 2020+0.3%-8.7%+2.9%
Q1 2020-9.9%-12.2%+9.1%
Q4 2019+0.4%+0.1%-39.5%
Q3 2019+32.1%+21.5%+3.7%
Q2 2019+29.1%+31.0%+37.2%
Q1 2019+19.6%+21.5%+15.9%
Q4 2018-15.3%-18.8%-26.5%
Q3 2018-11.0%-13.6%-13.9%
Q2 2018+18.6%+15.0%+20.8%
Q1 2018-22.9%-15.7%-8.6%
Q4 2017-4.0%-11.3%-17.4%
Q3 2017-8.0%-9.2%-8.0%
Q2 2017+7.1%+6.0%+9.3%
Q1 2017-5.5%-1.8%+0.4%
Q4 2016-5.0%-5.1%-16.4%
Q3 2016+2.0%+2.7%+8.0%
Q2 2016-5.0%-2.3%-6.7%
Q1 2016+0.5%
Q4 2015+11.2%
Q3 2015+12.5%
Q2 2015+3.2%
Q1 2015-7.5%
Q4 2014-10.7%
Q3 2014+1.0%
Q2 2014+4.1%
Q1 2014+7.7%
Q4 2013+26.9%
Q3 2013+6.5%
Q2 2013+21.9%
Q1 2013-1.8%
Q4 2012+16.6%
Q3 2012-7.7%
Q2 2012+24.4%
Q1 2011+0.6%
Q1 2012+2.8%
Q4 2009+1.5%
Q4 2011+1.5%
Q3 2011+7.0%
Q3 2010+7.0%
Q2 2010-3.4%
Q4 2010-3.4%
Q2 2011-3.4%
Q1 2010-1.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro